Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Diabetes Reports

• Publication date

  2017-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11892-017-0868-1PMID 28451949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes.

  2016cited by this paper
• Pragmatic Trials.

  2016cited by this paper
• Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection

  2013cited by this paper
• The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

  2010cited by this paper
• Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

  2008cited by this paper
• Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype

  2008cited by this paper
• Downregulation of the Hemoglobin Scavenger Receptor in Individuals With Diabetes and the Hp 2-2 Genotype: Implications for the Response to Intraplaque Hemorrhage and Plaque Vulnerability

  2007cited by this paper
• Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial

  2007cited by this paper
• Differential Association of Hemoglobin with Proinflammatory High Density Lipoproteins in Atherogenic/Hyperlipidemic Mice

  2007cited by this paper
• Mechanisms of Disease: proatherogenic HDL—an evolving field

  2006cited by this paper
• Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction.

  2005cited by this paper
• Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality

  2005cited by this paper
• Chronic Conditions, Functional Limitations, and Special Health Care Needs of School-Aged Children Born With Extremely Low-Birth-Weight in the 1990s

  2005cited by this paper
• The discovery of the antioxidant function of vitamin E: the contribution of Henry A. Mattill.

  2005cited by this paper
• The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

  2004cited by this paper
• Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes.

  2003cited by this paper
• Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

  2003cited by this paper
• Genetically Determined Heterogeneity in Hemoglobin Scavenging and Susceptibility to Diabetic Cardiovascular Disease

  2003cited by this paper
• Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.

  2002cited by this paper
• Scalp cooling therapy and cytotoxic treatment.

  2001cited by this paper
• Identification of the haemoglobin scavenger receptor

  2001cited by this paper
• Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.

  2000cited by this paper
• The prevalence of type II diabetes mellitus is haptoglobin phenotype-independent.

  2000cited by this paper
• Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection.

  2000cited by this paper
• Vitamin E supplementation and cardiovascular events in high-risk patients.

  2000cited by this paper
• Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease.

  1998cited by this paper
• Biological and clinical significance of haptoglobin polymorphism in humans.

  1996cited by this paper
• High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport.

  1996cited by this paper
• An overview of reverse cholesterol transport.

  1994cited by this paper
• Vitamin E consumption and the risk of coronary heart disease in men.

  1993cited by this paper
• Vitamin E consumption and the risk of coronary disease in women.

  1993cited by this paper
• Recycling of vitamin E in human low density lipoproteins.

  1992cited by this paper
• Acute‐phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin‐1 and interleukin‐6

  1991cited by this paper
• Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

  1989cited by this paper
• Vitamin E in young and old human red blood cells .

  1986cited by this paper
• Structure and assembly of haptoglobin polymers by electron microscopy.

  1984cited by this paper
• Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation.

  1982cited by this paper
• The first two decades of vitamin E.

  1977cited by this paper
• On the quenching of singlet oxygen by alpha-tocopherol.

  1974cited by this paper
• ON THE QUENCHING OF SINGLET OXYGEN BY α‐TOCOPHEROL

  1974cited by this paper
• Probable Assignment of the Alpha Locus of Haptoglobin to Chromosome 16 in Man

  1969cited by this paper
• The role of haptoglobin in the clearance and distribution of extracorpuscular hemoglobin.

  1961cited by this paper

• The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment

  2025cites this paper
• Haptoglobin Polymorphisms: Translational Insights and Regenerative Potential in Disease Management

  2025cites this paper
• Development of Subtle Iron Deficiency During Vitamin E Treatment For Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• Haptoglobin polymorphism, vitamin E and mortality: the Ludwigshafen Risk and Cardiovascular Health Study

  2024cites this paper
• Choline consumption reduces CVD risk via body composition modification

  2024cites this paper
• Genotyping and phenotyping of Haptoglobin gene polymorphisms and their correlation with cardiovascular disease and biochemical parameters in Iranian patients with type 2 diabetes mellitus

  2024cites this paper
• Association of HDL-Cholesterol, hypertension and left ventricular hypertrophy in youths with overweight or obesity.

  2023cites this paper
• Unlocking the link between haptoglobin polymorphism and noninfectious human diseases: insights and implications

  2023cites this paper
• Role of vitamins in the metabolic syndrome and cardiovascular disease

  2021cites this paper
• 抗酸化ビタミンのヒト研究の最新情報

  2021cites this paper
• Nutrients and Dietary Approaches in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Narrative Review

  2021cites this paper
• Haptoglobin Gene Polymorphism among Sickle Cell Patients in West Cameroon: Hematological and Clinical Implications

  2021cites this paper
• The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes

  2020cites this paper
• Vitamin E Intake Is Associated with Lower Brain Volume in Haptoglobin 1-1 Elderly with Type 2 Diabetes

  2020cites this paper
• Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis

  2020cites this paper
• Nitric Oxide Mediates Inflammation in Type II Diabetes Mellitus through the PPARγ/eNOS Signaling Pathway

  2020cites this paper
• Implications of Haptoglobin Genotype and Cardiovascular Risk in Patients with Diabetes

  2020cites this paper
• Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis

  2019cites this paper
• Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes

  2019cites this paper
• Ageing, Age-related Diseases and Oxidative Stress: What to Do Next?

  2019cites this paper
• Preventive Effect of Polyunsaturated Fatty Acid and Vitamin E in Rice Bran Oil on Lifestyle-Related Diseases.

  2019cites this paper
• Activation of human insulin by vitamin E: A molecular dynamics simulation study.

  2019cites this paper
• Clinical Cardiovascular Disease Trials: The Vitamin E Case

  2019cites this paper
• Vitamin E and Mortality: A Critical Perspective of the Conflicting Meta-analysis Outcomes

  2019cites this paper
• The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it

  2019cites this paper
• Vitamin E: Regulatory role in the cardiovascular system

  2019cites this paper
• The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus

  2018cites this paper